Epidemiology of liver diseases: global disease burden and forecasted research trends
Science China Life Sciences · 2025-02 · 68 (2) · 541-557
DOI: 10.1007/s11427-024-2722-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Science China Life Sciences, online erschienen am 16.10.2024. Verfasst von Jia Xiao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266071, China. edwinsiu@connect.…. Hauptthemen laut MEDLINE: Liver Diseases, Global Burden of Disease. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 94 Literaturangaben.
Abstract (Originalsprache)
We assessed the global incidence, mortality, and disability-adjusted life years (DALYs) associated with various liver diseases, including alcohol-related liver disease (ALD), hepatitis B/C virus infections (HBV or HCV), liver cancer, metabolic dysfunction-associated steatotic liver disease (MASLD), and other chronic liver diseases, from the 2019 Global Burden of Disease study. Additionally, we analyzed the global trends in hepatology research and drug development. From 2000 to 2019, prevalence rates increased for ALD, MASLD and other liver diseases, while they decreased for HBV, HCV, and liver cancer. Countries with a high socio-demographic index (SDI) exhibited the lowest mortality rates and DALYs. The burden of liver diseases varied due to factors like sex and region. In nine representative countries, MASLD, along with hepatobiliary cancer, showed highest increase in funding in hepatology research. Globally, the major research categories in hepatology papers from 2000 to 2019 were cancer, pathobiology, and MASLD. The United States (U.S.) was at the forefront of hepatology research, with China gradually increasing its influence over time. Hepatologists worldwide are increasingly focusing on studying the communication between the liver and other organs, while underestimating the research on ALD. Cancer, HCV, and MASLD were the primary diseases targeted for therapeutic development in clinical trials. However, the proportion of new drugs approved for the treatment of liver diseases was relatively low among all newly approved drugs in the U.S., China, Japan, and the European Union. Notably, there were no approved drug for the treatment of ALD in the world.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, 266071, China. edwinsiu@connect.hku.hk.
- Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, 510630, China. edwinsiu@connect.hku.hk.
- Division of Gastroenterology, Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518107, China.
- School of Biological Sciences, Jinan University, Guangzhou, 519070, China.
- Aier Institute of Ophthalmology, Central South University, Changsha, 410015, China.
- Lab of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Zitieren
APA
Xiao, J., Wang, F., Yuan, Y., Gao, J., Xiao, L., Yan, C., Guo, F., Zhong, J., Che, Z., Li, W., Lan, T., Tacke, F., Shah, V. H., Li, C., Wang, H., & Dong, E. (2025). Epidemiology of liver diseases: global disease burden and forecasted research trends. Science China Life Sciences, 68(2), 541-557. https://doi.org/10.1007/s11427-024-2722-2
Vancouver
Xiao J, Wang F, Yuan Y, Gao J, Xiao L, Yan C, et al. Epidemiology of liver diseases: global disease burden and forecasted research trends. Science China Life Sciences. 2025;68(2):541-557. doi:10.1007/s11427-024-2722-2
BibTeX
@article{Xiao2025,
author = {Xiao, Jia and Wang, Fei and Yuan, Yuan and Gao, Jinhang and Xiao, Lu and Yan, Chao and Guo, Feifei and Zhong, Jiajun and Che, Zhaodi and Li, Wei and Lan, Tian and Tacke, Frank and Shah, Vijay H and Li, Cui and Wang, Hua and Dong, Erdan},
title = {Epidemiology of liver diseases: global disease burden and forecasted research trends},
journal = {Science China Life Sciences},
year = {2025},
volume = {68},
number = {2},
pages = {541--557},
doi = {10.1007/s11427-024-2722-2}
}
EUVIMED